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Liver metastases of colorectal cancer 
— what are the limitations  
of multimodality treatment?
ABSTRACT
The prognosis of patients with liver-only metastases of colorectal cancer varies significantly, depending mostly 
on technical resectability of metastases. Possible treatment modalities include surgical resection, methods of 
local ablative treatment, as well as systemic chemotherapy. Hereunder, we present a case of a 52-year-old male 
patient with colon cancer metastases limited initially to the liver, who underwent multimodality treatment consisting 
of systemic chemotherapy and several forms of localised treatment: radioembolisation, non-anatomical resection 
and thermoablation of liver metastases, and wedge resection of lung metastasis. Despite achieving long-lasting 
control of liver metastases, localised treatment resulted also in chronic thrombocytopaenia, which prevented 
introduction of optimal subsequent systemic treatment. 
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Introduction
Patients with colorectal cancer (CRC) with liver-only 
metastases have varied prognosis, which depends mostly 
on prognostic factors related to the cancer itself and on 
the technical possibility of implementing radical local 
treatment, mostly surgical resection [1]. Unfavourable 
prognostic factors related to cancer include: synchro-
nous or metachronous type of developing metastases, 
disease-free survival time from primary resection, 
number and volume of metastases, and the presence 
or suspicion of extrahepatic metastases. Tools for risk 
evaluation that include prognostic factors, such as Fong 
score [2], allow estimation of the potential disease-free 
survival and provide guidance in selecting the most suit-
able candidates for surgical treatment. 
Treatment of patients with initially resectable liver 
metastases consist mostly of surgical resection, which 
may or may not be supported by administration of sys-
temic chemotherapy. Such a surgical-only approach re-
sults in five-year survival rates reaching nearly 50% [3]. 
The addition of perioperative chemotherapy, most com-
monly FOLFOX or CAPOX regimens, improve pro-
gression-free survival (PFS) without unequivocal sta-
tistical evidence for prolongation of overall survival [3]. 
Inclusion of currently available targeted therapies 
used in metastatic colorectal cancer into periopera-
tive chemotherapy failed to improve long-term results 
[1]. In cases of liver-only metastases unambiguously 
unsuitable for radical treatment, even after achieving 
tumour response, the treatment of choice consists of 
palliative chemotherapy supported by methods of local 
and locoregional treatment when justified. Methods 
of local treatment applicable in such cases include: 
thermoablation [radiofrequency ablation (RFA) or 
microwave ablation] [4], stereotactic body radiotherapy 
(SBRT) [5], chemoembolization [6], or radioembolisa-
tion such as selective internal radiation therapy (SIRT) 
[7]. The major limitation of implementing local and lo-
coregional methods in patients not suitable for radical 
treatment is insufficiency of good quality prospective 
data showing improvement in OS because most previ-
ously conducted studies have reported improvement 
in PFS only [8]. 
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The subsequent group, which requires a different 
clinical approach, includes patients with initially unre-
sectable liver metastases who might be candidates for 
radical treatment after achieving tumour regression. 
In most of those cases, systemic chemotherapy would 
be the treatment of choice, with or without addition 
of local ablative methods. No standard fit-for-all 
chemotherapy regimen have been established in this 
setting with similar uncertainties regarding role of 
targeted therapy. However, considering the correla-
tion of response rate with rates of R0 resection, several 
combinations of chemotherapy with targeted therapies 
have been recommended. This includes the doublet of 
chemotherapy (FOLFOX/FOLFIRI) in conjunction 
with monoclonal antibody targeting epidermal growth 
factor receptor (EGFR), such as cetuximab, in patients 
without RAS gene family [9] as well as chemotherapy 
triplet (FOLFOXIRI) or doublet (FOLFOX/FOLFIRI) 
with monoclonal antibody targeting vascular endothelial 
growth factor (VEGF) bevacizumab in patients with veri-
fied RAS gene family mutation [10]. In clinical practice, 
selection of the right therapy remains difficult in most of 
the patients. An experienced multidisciplinary tumour 
board, consisting of an oncological surgeon (sometimes, 
depending on the clinical situation, this may also include 
a hepatobiliary surgeon and thoracic surgeon), medical 
oncologist, radiation oncologist, radiologist (in some 
cases also an interventional radiologist), and pathologist, 
should provide expertise and guidance in the most chal-
lenging cases. An appropriate combination of systemic, 
local, and locoregional therapy as well as development of 
convenient multidisciplinary cooperation may translate 
into substantial improvement of prognosis in patients 
with liver-only metastases from colorectal cancer. Never-
theless, complicated and multistage treatment caries the 
risk of additional adverse events, which in certain cases 
can constrict available treatment modalities. Hereunder, 
we report a case of a patient who, despite achieving 
impressive locoregional control of liver metastases, 
developed chronic toxicity that contraindicated further 
optimal systemic treatment. 
Case report
A 52-year old patient, K. R., initially without any 
comorbidities, was diagnosed with colon cancer after 
pathological examination of a biopsy specimen taken 
during colonoscopy in July 2014. USG showed multi-
ple, metachronous metastases in the liver, and this was 
confirmed in a CT scan of the abdomen performed on 
21.07.2014, which demonstrated the presence of five liver 
lesions measuring from 18 to 54 mm. On 14.08.2014 the 
patient underwent laparoscopic resection of the sigmoid 
colon, and the pathology report confirmed the diagnosis 
of colon cancer (adenocarcinoma tubulare G2, pT3 N1b, 
without confirmed mutations in RAS gene family). Due 
to the presence of multiple liver metastases, probably 
unresectable, the patient’s treatment was qualified as 
palliative, and on 10.10.2014 a FOLFIRI chemotherapy 
regimen was initiated. After the first cycle the patient 
developed neutropaenia [grade 4 according to Common 
Terminology Criteria for Adverse Events (CTCAE)], 
which reoccurred on a regular basis during further 
treatment as grade 3 neutropaenia and required 20% 
reduction in chemotherapy doses, prolongation of inter-
vals between chemotherapy cycles, and periodic support 
with granulocyte colony-stimulating factors. A CT scan 
taken after seven cycles of chemotherapy showed 13% 
regression in liver lesions (stable disease [SD], according 
to RECIST criteria). However, in a CT scan after 12 cy-
cles liver tumours grew by 5%, which did not fulfil cri-
teria for progression (Fig. 1A). At that time the patient 
was referred to a hepatobiliary surgeon, who qualified 
the liver metastases to be potentially resectable after 
achieving further regression. As initial chemotherapy 
with the FOLFIRI regimen showed moderate activity 
and simultaneously resulted in significant haematolog-
ical toxicity, achieving further regression with chemo-
therapy escalation or regimen change seemed unlikely. 
After a discussion with the interventional radiologist, 
locoregional treatment with radioembolisation (SIRT) 
was proposed as a modality to induce regression of liver 
metastases. SIRT was performed on 09.07.2015, during 
an interval between chemotherapy cycles, without any 
complications (Fig. 2). A CT scan from 07.09.2015, tak-
en after SIRT and 18 cycles of chemotherapy, showed 
a 19% reduction in the diameter of liver lesions (Fig. 1B). 
The response was confirmed on a PET-CT from 
18.09.2015, which additionally excluded the presence 
of extrahepatic metastases. Therefore, the patient was 
qualified for two-stage surgical resection of liver me-
tastases. Systemic treatment was withheld in October 
2015 after 21 cycles of FOLFIRI. On 11.12.2015 the 
patient underwent the first stage of surgical treatment: 
non-anatomical resection of liver metastases within the 
left lobe of the liver and right portal vein ligation to in-
duce hypertrophy of liver remnants. Unfortunately, the 
procedure resulted in occurrence of a vast haematoma 
within the left lobe of the liver (about 30–40% of the 
lobe volume) and no sign of liver remnant hypertro-
phy was seen during follow-up. Therefore, the second 
stage of surgical treatment had to be abandoned due 
to high risk of postsurgical liver failure. The next CT 
scan taken on 15.01.2016 showed additional regression 
of metastases left within the right lobe of the liver af-
ter the surgical procedure. The obtained reduction in 
lesion diameter reached 31%, which corresponded to 
partial response (PR) according to RECIST criteria 
(Fig. 1C). Regarding achieved disease control and 
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Figure 1. CT images showing changes in liver metastases: A — scan before radioembolisation; B — scan 2 months after 
radioembolisation; C — scan 4 months after radioembolisation and after resection of metastasis from left lobe of liver (*marks 
post-surgical haematoma); D — scan 2 years after radioembolisation (*marks residuary fluid collection from haematoma, arrow 
indicates presence of new metastasis)
previous toxicity of systemic treatment, the decision 
about withholding chemotherapy was sustained and 
the patient was only under follow-up. Disease pro-
gression was detected after a PET-CT performed on 
31.05.2016 showed a metabolically active 10-mm lesion 
in the third segment of the left lung — progression-free 
survival (PFS) was 10.9 months since carrying out the 
SIRT procedure and 19.9 months since introduction 
of FOLFIRI chemotherapy. However, the liver lesion 
left within the right lobe of the liver continued to de-
cline. Despite the suggestion of local treatment of lung 
metastasis, the patient decided to continue further 
follow-up only. A CT scan from 16.11.2016 confirmed 
growth of the lung lesion (now 13 mm) as well as the 
presence of a new lesion in the liver 12 mm in diameter, 
which resulted in liver-only PFS of 16.5 months since 
SIRT procedure. At this point, a chronic decrease of 
platelet count to about 100-150 × 109/L was observed 
for the first time. The patient was offered second-line 
chemotherapy with FOLFOX4 + bevacizumab, but 
he decided to attempt radical treatment for both lung 
and liver metastases. On 01.02.2017 transabdominal 
USG-guided thermoablation of the liver lesion was 
performed, and on 20.03.2017 wedge resection of the 
lung metastasis was carried out. However, a subsequent 
CT scan from 05.04.2017 revealed further progression 
Figure 2. SPECT/CT imaging after intra-arterial administration 
of yttrium-90 resin microspheres showing acquisition of 
radiation within liver metastases
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inability to carry out both stages of the procedure, had 
the potential to radically resect all present metastases, 
a factor known to improve prognosis [1]. Extra consid-
eration should be given to the possibility of interaction 
between SIRT, which involves embolisation of hepatic 
arteries using yttrium-90 resin microspheres, and right 
portal vein ligation — because alteration of both arter-
ies and veins of the hepatic vascular system could block 
sufficient liver hypertrophy. In terms of thermoablation, 
a successful procedure could radically ablate the source 
of local progression and postpone the need for systemic 
treatment, especially if we consider that no other le-
sion appeared during further follow-up. However, 
because the liver metastasis progressed immediately in 
the next CT scan, it may indicate that thermoablation 
under USG guidance missed the targeted lesion, and 
therefore commencing second-line chemotherapy was 
required. Value of wedge resection of lung metastasis 
and its timing remain unclear, particularly considering 
the low volume and slow growth dynamics of the lesion. 
Long-term toxicity, thrombocytopaenia, attributed to 
the used techniques of local and locoregional treat-
ment, was not significant from a clinical perspective. 
Nevertheless, due to the strict criteria of NFZ drug reim-
bursement, thrombocytopaenia disqualified the patient 
from access to targeted therapies with a proven positive 
effect on overall survival (bevacizumab in second-line 
treatment and cetuximab/panitumumab in subsequent 
lines). The question of whether the benefit that the 
presented patient derived from locoregional treatment 
outweighs the loss from suboptimal systemic treatment, 
remains open. Overall survival for the patient from the 
initiation of chemotherapy reached 34.3 months and 
is ongoing. This significantly exceed the median OS 
achieved in clinical trials assessing not only first-line 
treatment with FOLFIRI regimen itself (20.6 months 
in GERCOR trial [11]), but also median OS obtained 
with a combination of FOLFIRI with targeted thera-
pies (28.7 months for FOLFIRI with cetuximab and 
25 months for FOLFIRI with bevacizumab, both results 
from the FIRE-3 trial [12]). Another open issue involves 
quality of life — long-term local control secured with 
SIRT procedure allowed the patient to remain without 
systemic treatment and its negative burden for nearly 
18 months. During this period, he remained asympto-
matic and able to maintain a full-time job. The compli-
cated fortunes of the presented patient are an explicit 
example on how modern management of CRC require 
multidisciplinary collaboration. Only rigorous partner-
ship between different medical specialists allows the 
proper combination of different modalities to be chosen, 
in proper patients and in proper time. In the end, only 
strict collaboration can enable the full potential that 
lies within multimodality treatment and translate this 
potential into real clinical benefit for patients with CRC.
of the liver lesion to 51 mm, without the possibility of 
subsequent localised treatment (Fig. 1D). Although 
the patient agreed to start second-line chemotherapy, 
laboratory results confirmed chronic thrombocytopae-
nia (grade 2 CTCAE) 50–100 × 109/L, unresponsive to 
a short-course of steroids. 
Etiopathogenesis of thrombocytopaenia remained 
unclear — according to the consulting haematologist, 
the presence of thrombopoietic suppressive factors 
secreted by neoplasm might be responsible, but se-
questration of platelets in the disturbed vascular system 
of liver remnants may also occur. Chronic thrombo-
cytopaenia excluded the patient from the National 
Health Fund (NFZ) program of bevacizumab access in 
second-line treatment of CRC and prevented further 
access to panitumumab/cetuximab NFZ programs. Since 
21.04.2017 the patient has received FOLFOX4 chemo-
therapy with 20% dose reduction and prolongation of 
cycle intervals because it allows us to conduct treatment 
without hazardous falls of the platelet count below 
50 × 109/L. In the first CT scan obtained after FOLFOX4 
introduction, the dimension of measurable lesions de-
clined by 6%, including the previously fast-progressing 
liver lesion. The achieved stabilisation provides hope 
for gaining control over the disease. This would allow 
further prolongation of the patient’s overall survival, 
which has currently reached nearly 35 months since 
first-line chemotherapy introduction.
Discussion
The presented case clearly shows how complex and 
peculiar modern CRC management can be. The devel-
opment of, and growing access to, novel methods of local 
and locoregional treatment, as well as the combination 
of those methods with systemic treatment, can be used 
to provide tailored treatment that addresses the needs of 
each patient individually. However, this may come at the 
price of increased toxicities that complicate subsequent 
management. In the presented patient, treatment with 
SIRT provided long-term disease control in the liver 
(16.5 months), despite earlier extrahepatic progression 
(10.9 months). The finding comes along with the results 
of the SIRFLOX trial [7], in which a combination of ra-
dioembolisation with systemic chemotherapy, compared 
to systemic chemotherapy alone, prolonged liver-only 
median PFS (20.5 vs. 12.6 months, respectively) without 
any effect on global median PFS (10.7 vs. 10.2 months, 
respectively). It should be emphasised that in the pre-
sented case neither of the liver lesions covered with the 
SIRT procedure have yet progressed (during a period 
of 25.2 months). The effects of other implemented 
modalities on the fate of the discussed patient are more 
difficult to weigh up. The surgical approach, despite the 
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